Castle Biosciences Raises FY2026 Sales Guidance from $340.000M-$350.000M to $345.000M-$355.000M vs $345.734M Est

Benzinga Newsdesk www.benzinga.com Positive 94.1%

Neg 0% Neu 0% Pos 94.1%

Castle Biosciences (NASDAQ:CSTL) raises FY2026 sales outlook from $340.000 million-$350.000 million to $345.000 million-$355.000 million vs $345.734 million estimate.